current developments in fgfr inhibitors for urothelial cancer
Published 1 year ago • 55 plays • Length 0:43Download video MP4
Download video MP3
Similar videos
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
2:27
advances in fgfr inhibition for hepatobiliary cancer
-
2:53
effect of fgfr status on checkpoint inhibitor response in bladder cancer
-
1:17
recent advances in the treatment of upper tract urothelial carcinoma
-
9:55
fgfr inhibitors in development for cca
-
2:52
fgfri treatment-emergent aes in urothelial cancer
-
2:02
the evolving treatment landscape for urothelial cancer
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
2:48
fgfr inhibitors in bladder cancer
-
2:29
additional insights: experience with fgfr inhibitors in bladder cancer
-
1:23
recent advances in the use of targeted therapies for metastatic urothelial carcinoma
-
11:42
fgfr inhibitors in bladder cancer: testing, screening and highlights from asco 2020
-
6:24
fgfr3 inhibitors for upper tract urothelial cancer
-
1:15
treating advanced/metastatic urothelial carcinoma: recent developments in the bgj398 clinical trial
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
3:12
the development of fgfr inhibitors
-
3:42
norse: erdafitinib cetrelimab in muc with fgfr alterations
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
2:27
pan-fgrf inhibitors in different fgfr alteration types across solid tumours